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Abstract
Virtual compound screening using molecular docking is widely used in the discovery of new lead compounds for drug
design. However, this method is not completely reliable and therefore unsatisfactory. In this study, we used massive
molecular dynamics simulations of protein-ligand conformations obtained by molecular docking in order to improve the
enrichment performance of molecular docking. Our screening approach employed the molecular mechanics/Poisson-
Boltzmann and surface area method to estimate the binding free energies. For the top-ranking 1,000 compounds obtained
by docking to a target protein, approximately 6,000 molecular dynamics simulations were performed using multiple
docking poses in about a week. As a result, the enrichment performance of the top 100 compounds by our approach was
improved by 1.6–4.0 times that of the enrichment performance of molecular dockings. This result indicates that the
application of molecular dynamics simulations to virtual screening for lead discovery is both effective and practical.
However, further optimization of the computational protocols is required for screening various target proteins.
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Introduction
In early-phase drug development research, new lead com-
pounds are detected by the computational screening of large
compound libraries. Since the goal of computational screening is
basically the same as that of experimental screening, i.e., high-
throughput screening (HTS), it is expected that the integration and
improvement of computational and experimental approaches will
increase the productivity of drug discovery. HTS is currently
widely adopted and is crucial to the generation of lead compounds.
Despite the many successes achieved with HTS [1–5], there
remain some problems regarding the cost, complexity of the assay
procedure, and screening quality [5–8]. Thus, HTS alone may not
improve lead productivity. Hence, computational screening
methods, such as ligand- and structure-based screening, have
become important. With the advancement of computer perfor-
mance and calculation techniques, computational screening has
become faster and less expensive than HTS. However, the ability
of computational screening to enrich hit compounds remains
unsatisfactory and less reliable.
Coupled with a rapidly rising number of structures for target
proteins, structure-based screening has become prominent in drug
discovery. Among the various structure-based computational
methodologies adopted for compound screening, the principal
one is molecular docking. When the three-dimensional structure of
a target protein is available or can be modeled, molecular docking
is often used for the screening of compound libraries. Molecular
docking predicts the conformation of a protein-ligand complex
and calculates the binding affinity. Most docking programs [9–15]
involve two operations: ‘‘docking’’ and ‘‘scoring.’’ The first
involves the generation of multiple protein-ligand conformations,
called ‘‘poses,’’ or the sampling of the ligand’s probable
conformations in the binding pocket of the target protein. Most
of these programs perform flexible ligand-rigid receptor docking,
and some of them are highly capable of predicting poses that
resemble the experimental structure for many target proteins [16].
Since such docking programs enable a fast conformational search
of ligands in a short time, they are very attractive tools for
compound screening. In the second operation, the affinity between
the target protein and the ligand for each pose is calculated by
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according to these calculated binding affinities or docking scores.
Many studies using docking programs have shown that these
screenings have a higher enrichment of hits than random
screening [17,18], but these screenings suffer from false positives
and false negatives and are not sufficiently accurate to grade
compounds according to the binding affinities [19]. This implies
that the compounds with a higher rank include false positives and
false negatives; thus, there is a practical difficulty with using
docking. The problems of molecular docking as a screening tool
have been widely discussed: the scoring functions are inaccurate
and neglect the solvent-related terms, and protein flexibility is
ignored. Furthermore, the docking score corresponding to binding
free energy is less reliable because it is calculated using a single
conformation even though the binding free energy is an ensemble
property.
Molecular dynamics (MD) simulations can treat both proteins
and ligands in a flexible manner, allowing the relaxation of the
binding site around the ligand. In addition, they can directly
estimate the effect of explicit water molecules. Further, more
accurate MD-based computational techniques are available for
estimating the binding free energy. These techniques include
thermodynamic integration (TI) [20], free energy perturbation
(FEP) [20], linear interaction energy (LIE) [21], and molecular
mechanics/Poisson-Boltzmann and surface area (MM/PB-SA)
[22] methods. The most rigorous computational techniques are
the TI and FEP methods, but these are too expensive to be
employed in computational screening. The computational cost of
LIE is moderate, but it requires information regarding the binding
affinities of experimentally known compounds. Hence, we focused
on the MM/PB-SA method because many recent investigations
have revealed that this method is highly capable of predicting the
binding free energy [23]; further, its computational cost is lower
than the computational costs of the FEP and TI methods by at
least 10-fold, and its broad applicability is suitable for compound
screening. In the MM/PB-SA method, the free energy is
calculated using the snapshots of solute molecules obtained from
explicit-solvent MD simulation. At this time, the explicit-solvent is
replaced with implicit models (see Materials and Methods). These
MD-based techniques can provide more accurate binding free
energy, but their computational costs are considerably high, as
compared to molecular docking. Further, the prediction of the
optimal structures for protein-ligand complexes adds to the
computational cost, even with extended-ensemble MD methods.
To solve the problem of molecular docking and MD
simulations, a combination of molecular docking and MD
simulations is effective because it can neutralize each other’s
defects. However, since the application of the MD technique to
screening requires the execution of many MD simulations, the
problem of the high computational cost of MD simulations
remains unresolved. Because of this problem, most of the studies
that have used MD-based computational techniques have reported
only their ability to rank several ligands according to their
experimental binding affinities [23,24]. Further, since the most
important parameter for screening is the ability to distinguish true
active compounds from a large number of inactive compounds,
only a few researches have assessed the ability to enrich active
compounds by virtual screening using MD-based computational
techniques [25,26].
In order to reduce the significant computational cost of MD
simulations, we used a special-purpose computer for MD
simulations, ‘‘MDGRAPE-3,’’ which functions with a high speed
and accuracy [27,28]. In this study, we performed MD simulations
of multiple protein-ligand conformations (multiple poses) rather
than a single protein-ligand conformation (single pose). The
multiple protein-ligand conformations were obtained from the
result of molecular docking. Multiple poses were used so that the
multiple local energy minima in the ligand’s conformational space
within the binding pocket could be sampled in the initial structures
for MD simulations. Then, we performed massive MD simulations
using multiple poses in a practically appropriate time for drug
discovery.
In our screening approach, we adopted molecular docking and
the MM/PB-SA method as the first and second filters for
compound screening; this idea was inspired by the approach
adopted by Kuhn and coworkers [25]. They made some
important discoveries with respect to MD-based screening for
lead generation. Their results showed that the application of the
MM/PB-SA method to an energy-minimized complex structure is
an adequate and more accurate approach than the calculation of
the binding free energy using MD simulation. This is because the
use of MD simulations introduces additional structural uncertain-
ties and the free energy from the MD simulations leads to
inaccuracy. Further, they reported that the strategy of using
multiple poses cannot be recommended in general, and is useful
only if the correct binding mode is contained within the higher-
scored docking conformations but is not captured with a single
pose. Their MD simulations were applied to the protein-ligand
complexes for the top 200 compounds obtained by molecular
docking, and the MD run for each complex was performed for
200 ps (with a time step of 1.5 fs). They concluded that a more
sophisticated MD procedure involving an extended simulation
time improved the results, although this time-consuming approach
would not be of considerable interest as a tool for lead discovery.
In our study, we attempted to investigate whether a combina-
tion of molecular docking and massive-scale MD simulations
would be effective in screening compound libraries. Furthermore,
we evaluated which protocols for the MM/PB-SA method were
effective for compound screening. In the basic MD strategy for our
compound screening, a 700-ps MD simulation (with a time step of
Author Summary
Lead discovery is one of the most important processes in
rational drug design. To improve the rate of the detection
of lead compounds, various technologies such as high-
throughput screening and combinatorial chemistry have
been introduced into the pharmaceutical industry. How-
ever, since these technologies alone may not improve lead
productivity, computational screening has become impor-
tant. A central method for computational screening is
molecular docking. This method generally docks many
flexible ligands to a rigid protein and predicts the binding
affinity for each ligand in a practical time. However, its
ability to detect lead compounds is less reliable. In
contrast, molecular dynamics simulations can treat both
proteins and ligands in a flexible manner, directly estimate
the effect of explicit water molecules, and provide more
accurate binding affinity, although their computational
costs and times are significantly greater than those of
molecular docking. Therefore, we developed a special
purpose computer ‘‘MDGRAPE-3’’ for molecular dynamics
simulations and applied it to computational screening. In
this paper, we report an effective method for computa-
tional screening; this method is a combination of
molecular docking and massive-scale molecular dynamics
simulations. The proposed method showed a higher and
more stable enrichment performance than the molecular
docking method used alone.
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compounds obtained by docking. With regard to the time
resolution, simulation time, and number of protein-ligand complex
structures, our MD runs were more massive and elaborate than
those of previous MD-based screenings [25].
Overview of Our Approach
In our screening approach, we adopted molecular docking and
the MM/PB-SA method based on MD simulations as the first and
second filters, respectively. First, we performed molecular docking
by using the conformations of a target protein and the compounds
contained in the compound library. Additionally, the results of
molecular docking were applied to the post-processing for the
selection of successfully docked compounds and the classification
of multiple binding poses (see Materials and Methods). Next, all of
the conformations obtained from the molecular docking were
energy-minimized using molecular mechanics (MM) force-field
(hereafter we call this MM calculations). MD simulations were
then applied to multiple conformations of the protein-ligand
complexes. The binding free energies were calculated by the MM/
PB-SA method using the coordinate sets obtained from the MM
calculations and MD simulations. Finally, we assessed the
enrichment of active compounds by using ranked lists of
compounds graded on the basis of their binding free energies.
Results
To evaluate the ability of the MM/PB-SA method to act as a
filter after molecular docking, we performed MD-based compound
screening for four target proteins (trypsin, HIV-1 protease (HIV
PR), acetylcholine esterase (AChE), and cyclin-dependent kinase 2
(CDK2)). These targets have been widely evaluated in structure-
based computer-aided drug design [26,29–34]. For each target
protein, we first assessed the enrichment of 12 types of binding free
energies (Table 1). These 12 types of binding free energies were
classified into four categories. G01–G03 in category 1 were the
energies calculated from the MM calculations. The other
categories 2–4, which contained the energies calculated from the
MD simulations, were classified according to the combination of
coordinate sets used for the enthalpy calculations; G04–G06,
G07–G09, and G10–G12 belonged to categories 2, 3, and 4,
respectively (a detailed explanation is given in the Materials and
Methods section.). Analyses of the Receiver Operating Charac-
teristic (ROC) curves [35] are given in Table 2. An ROC curve is
closely related to an enrichment curve but is not exactly equivalent
to it. This curve describes the tradeoff between sensitivity and
specificity. Sensitivity is defined as the ability of the classifier to
detect true positives, while specificity is the ability to avoid false
positives. The area under an ROC curve, i.e., the ROC value,
indicates the quality of enrichment. The ROC value of a random
classifier is 0.5, while that of an excellent classifier is greater than
0.9.
Table 2 shows the ROC values for all of the target proteins.
From these values, we can observe three common features for
three of the target proteins (trypsin, HIV PR, and AChE),
excluding CDK2. It is obvious that the ROC values for all of the
binding free energies (G01–G12) of multiple poses are higher than
those of a single pose, suggesting that docking and its post-
processing can sample potentially correct docking poses of active
compounds. This implies that the potentially correct binding mode
is contained within the top 10 highest-scored docking poses but is
not always the highest-scored docking pose. In our study, after
docking and post-processing, MD simulations were applied to an
average of 5–6 docking poses for each compound in order to
increase the efficiency of the sampling of a ligand’s conformations.
Although MD simulations of multiple poses are expensive, they are
necessary for improving enrichment.
The second common feature is that the highest ROC value for
each target protein was obtained for the energies calculated from
the MD simulations, rather than for those calculated from the MM
calculations. This implies that the introduction of protein flexibility
and the effect of water molecules facilitated the refinement of the
protein-ligand interactions and that the MD-based MM/PB-SA
method provided a more reliable binding free energy. These two
Table 1. Computational strategies of 12 binding free energies.
Category DGbind HCOMPLEX HPROTEIN HLIGAND TSCOMPLEX TSPROTEIN TSLIGAND
1G 0 1 M M COMPLEX MMCOMPLEX MMCOMPLEX –––
G02 MMCOMPLEX MMCOMPLEX MMLIGAND –––
G03 MMCOMPLEX MMPROTEIN MMLIGAND –––
2G 0 4 M D COMPLEX MDCOMPLEX MDCOMPLEX TSCOMPLEX TSCOMPLEX TSLIGAND
G05 MDCOMPLEX MDCOMPLEX MDCOMPLEX TSCOMPLEX TSPROTEIN TSLIGAND
G06 MDCOMPLEX MDCOMPLEX MDCOMPLEX –––
3G 0 7 M D COMPLEX MDCOMPLEX MDLIGAND TSCOMPLEX TSCOMPLEX TSLIGAND
G08 MDCOMPLEX MDCOMPLEX MDLIGAND TSCOMPLEX TSPROTEIN TSLIGAND
G09 MDCOMPLEX MDCOMPLEX MDLIGAND –––
4G 1 0 M D COMPLEX MDPROTEIN MDLIGAND TSCOMPLEX TSCOMPLEX TSLIGAND
G11 MDCOMPLEX MDPROTEIN MDLIGAND TSCOMPLEX TSPROTEIN TSLIGAND
G12 MDCOMPLEX MDPROTEIN MDLIGAND –––
We performed MM calculations (MM energy minimization) or MD simulations of a complex, a protein, and a ligand, and evaluated 12 types of binding free energies by
combining the respective coordinate sets. The enthalpy contributions of Gprotein and Gligand in equation 2 were calculated in the following two ways: (1) by using the
coordinate sets of a protein (or ligand) obtained from the MD simulations (or MM calculations) of the protein (or ligand) and (2) by using the coordinate sets extracted
from the MD simulation of a complex. Similar to the enthalpy contribution, the entropy contribution was also calculated by combining the respective MD coordinate
sets. H indicates the sum of ,EMM., ,GPB.,a n d,GSA. in equation 3, and TS indicates the entropy term in equation 3. MD COMPLEX (TSCOMPLEX), MDPROTEIN (TSPROTEIN),
and MDLIGAND (TSLIGAND) denote the use of MD coordinate sets for a complex, protein, and ligand, respectively. Similarly, MMCOMPLEX,M M PROTEIN,a n dM M LIGAND denote
the use of MM coordinate sets for a complex, protein, and ligand, respectively.
doi:10.1371/journal.pcbi.1000528.t001
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compounds. A typical successful example of MD simulations using
multiple poses is shown in Figure 1. In the crystal structure of
trypsin complexed with an inhibitor [36], the amidine group of the
inhibitor (Figures 1 and S1; active compound (13) of trypsin)
formed hydrogen bonds with the important residue Asp-180 in the
binding pocket. Further, the highest-scored docking pose was so
inaccurate that no important interactions were observed at all, but
the 7
th ranked docking pose was similar to that of the crystal
structure. In addition, the application of the MD simulation to the
7
th ranked docking pose appropriately improved the key hydrogen
bonds and the position of the naphthalene group and G06 value of
the 7
th ranked docking pose was the lowest in all the poses.
The last common feature was that the binding free energies with
no entropy terms (i.e., G06, G09, and G12), which were obtained
by using the trajectories of the MD simulations, showed the
highest ROC values in the respective energy categories (2–4).
Thus, the introduction of entropy terms tended to reduce
enrichment. This is probably due to the difficulty of computing
entropy values for the MM-PB/SA energy function. We will
further discuss this problem in the Discussion section. Our MD
simulations encouraged conformational relaxation, and the
binding enthalpy from the MM-PB/SA method could satisfacto-
rily increase the enrichment performance. However, the treatment
of binding entropy terms involves certain unsolved problems.
Here, we performed a statistical analysis using data on the ROC
values to evaluate the differences between key classifiers, G01
(multiple poses), G06 (multiple poses), and molecular docking
(Table 3). The program DBM MRMC version 2.1 was used in this
analysis [37–41]. From this analysis, it was obvious that the
differences in the ROC values between G06 and docking, and
those between G06 and rescoring (docking), were statistically
significant for trypsin and HIV PR, but the difference in the ROC
values between G06 and docking for AChE was not statistically
significant. On the other hand, the differences in the ROC values
between G01 and docking were not statistically significant for
trypsin, HIV PR, and AChE. An examination of the entire data
set indicated that the binding free energies of multiple poses,
especially G06, which was obtained from the MD trajectories of
just the protein-ligand complexes with no entropies, showed a high
and stable ability to enrich the active compounds.
This paper provides a detailed account of the ability of our
approach to discriminate active compounds from inactive ones.
Figure 2 shows the ROC curves for the respective target proteins.
Figure 1. Successful example of MD simulations using multiple
poses. The color codes for the stick models are as follows: yellow,
conformation of the inhibitor in the crystal structure; purple, 7
th-ranked
docking pose; and pink, conformation of the 7
th-ranked docking pose
after the MD simulation. In addition, the highest-scored docking pose is
shown by the wireframe model. The highest-scored docking pose
(wireframe model) is inaccurate, but the 7
th-ranked docking pose is
similar to that of the crystal structure. MD simulation of the 7
th-ranked
pose improved the key hydrogen bonds and the position of the
naphthalene group and G06 value of the 7
th ranked docking pose was
the lowest in all the poses.
doi:10.1371/journal.pcbi.1000528.g001
Table 2. Area under ROC curves.
DGbind Trypsin HIV PR AChE CDK2 CDK2(l)
G01 0.754 (0.318) 0.775 (0.696) 0.655 (0.597) 0.719 (0.685) 0.719 (0.685)
G02 0.651 (0.323) 0.561 (0.550) 0.719 (0.627) 0.595 (0.652) 0.595 (0.652)
G03 0.491 (0.283) 0.538 (0.492) 0.747 (0.554) 0.586 (0.604) 0.586 (0.604)
G04 0.623 (0.321) 0.789 (0.435) 0.527 (0.409) 0.597 (0.599) 0.659 (0.627)
G05 0.539 (0.291) 0.775 (0.425) 0.506 (0.436) 0.565 (0.585) 0.636 (0.614)
G06 0.765 (0.391) 0.979 (0.550) 0.831 (0.603) 0.558 (0.568) 0.624 (0.558)
G07 0.543 (0.300) 0.514 (0.373) 0.509 (0.413) 0.625 (0.623) 0.647 (0.638)
G08 0.486 (0.265) 0.528 (0.383) 0.513 (0.435) 0.586 (0.606) 0.635 (0.626)
G09 0.694 (0.388) 0.778 (0.471) 0.843 (0.645) 0.606 (0.610) 0.622 (0.616)
G10 0.431 (0.369) 0.336 (0.373) 0.654 (0.458) 0.667 (0.615) 0.614 (0.606)
G11 0.422 (0.327) 0.326 (0.389) 0.678 (0.464) 0.653 (0.604) 0.605 (0.602)
G12 0.526 (0.406) 0.516 (0.352) 0.735 (0.541) 0.631 (0.605) 0.612 (0.606)
This table lists the ROC values obtained when the active compounds in the top 1,000 compounds are all considered to be as true positive. The values in parentheses
denote the ROC values of a single pose, while the others denote those of multiple poses. The underlining indicates the highest ROC values in the respective categories.
CDK2(l) indicates the values of longer MD simulations (1.4 ns) of CDK2.
doi:10.1371/journal.pcbi.1000528.t002
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Trypsin HIV PR AChE CDK2
G01# 0.754 (0.010) 0.775(0.054) 0.655(0.117) 0.719 (0.064)
G06# 0.765 (0.092) 0.979(0.004) 0.831(0.135) 0.558 (0.065)
GOLD/Rescore# 0.476(0.099)/0.477(0.081) 0.621(0.102)/0.636(0.117) 0.614(0.159)/0.268(0.098) 0.679 (0.067)/0.530 (0.038)
P values(G01/Docking) 0.054 0.542 0.922 0.915
p values(G01/Rescore) 0.055 0.320 0.019* 0.102
p values(G06/Docking) 0.045* 0.039* 0.330 -
p values(G06/Rescore) 0.046* 0.014* 0.001* 0.712
This analysis was analyzed by the program DBM MRMC 2.1 [37–41]. This program uses a jackknife method [37] to assess the statistical significance of the observed
difference between two classifiers. The p-value (G06/Docking) in CDK2 is not shown because the ROC value of G06 was less than that of Docking. This analysis indicated
that the differences between G01 and G06 were not statistically significant (data not shown). The analyses were performed using results of multiple poses. ‘‘Rescore’’
indicate the result of rescoring approach (docking) (see Materials and Methods).
#These values are ROC values. Standard errors are shown in parentheses.
*Differences are considered statistically significant at p,0.05.
doi:10.1371/journal.pcbi.1000528.t003
Figure 2. ROC curves for the four target proteins. Each graph shows the sensitivity versus 1-specificity. These indicate the ROC curves obtained
when the active compounds in the top 1,000 compounds are all considered to be as true positive. The black dashed, sky blue solid, and sky blue
dashed lines indicate random screening, molecular docking and rescoring (docking), respectively. For trypsin, HIV PR, and AChE, the ROC curves of
the binding free energies (multiple poses) with the highest ROC values in the respective categories are shown. For CDK2, the curves of G01 (single
and multiple poses), G04 (single pose), G07 (multiple poses), and G10 (multiple poses) are shown. (s) and (m) indicate single pose and multiple poses.
doi:10.1371/journal.pcbi.1000528.g002
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ROC values in the respective categories, were observed for
trypsin, HIV PR, and AChE. Table 4 shows the information on
the enrichment factors to allow the abilities of the classifiers to be
understood clearly.
For trypsin, 10 active compounds (out of 21) were ranked in the
top 1,000 compounds (Figure S1). No significant difference was
observed in the results of molecular docking and random screening
for these top 1,000 compounds. Considerable improvement was
observed in the results of the MM calculations and MD
simulations. G01 and G06, in particular, showed high enrichment
performances, and the enrichment factors for the top 100
compounds were 5.00 and 4.00, respectively (see Table 4).
Furthermore, G06 detected no less than nine active compounds
in the top 300.
For HIV PR, 6 active compounds (out of 8) were ranked in the
top 1,000 compounds (Figure S2). A slightly better enrichment was
achieved by docking than by random screening. As seen in the
curves, we found drastically improved enrichment by G06. It
detected 6 active compounds in the top 100 compounds, and the
enrichment factor for the top 100 was 10.0 (Table 4).
For AChE, 7 active compounds (out of 14) were detected in the
top 1,000 compounds (Figure S3). We found that the enrichments
of G06 and G09 were considerably better than that of molecular
docking, although the difference in the ROC values between G06
(or G09) and docking was not statistically significant. Because there
was only a slight difference between G06 and G09, both of them
detected five active compounds in the top 100.
For CDK2, the ROC curves of the following representative
binding free energies were drawn: G01 (single and multiple
poses), G04 (single pose), G07 (multiple poses), and G10
(multiple poses). Seventeen active compounds (out of 26) were
ranked in the top-scoring 1,000 compounds (Figure S4). The
G01 of single and multiple poses as obtained from the MM
calculations showed higher enrichment than random screening;
however, there was no statistically significant difference between
the results of G01 and molecular docking (see Table 3). The G01
of single and multiple poses detected 10 active compounds in the
top 300 and showed only slightly higher enrichment factors than
molecular docking (Table 4). In contrast, G04, G07, and G10,
which were obtained from the MD simulations, remained
unchanged or worsened as compared to docking, although they
identified 6 or 7 active compounds in the top 200. Over all, the
enrichments for CDK2 were not at all improved as mentioned
above.
The ROC values for CDK2 showed a different tendency as
compared to those for the other three proteins (Table 2). Among
the 12 types of energies, the G01 of single and multiple poses
showed the highest values (0.685 and 0.719, respectively), which
implies that the enrichments of the MM calculations were better
than those of the MD simulations. Moreover, for 7 types of
energies (out of 12), the single pose results showed higher
enrichment than those of multiple poses. In addition, the binding
free energies with entropy terms showed slightly high enrich-
ment performances in the respective categories (2–4), which
were calculated from MD simulations. In particular, G04, G07,
and G10, which included the binding entropy effects of the
ligands, showed the highest ROC values in their respective
categories.
We monitored the mobility of ligand molecules in MD
simulations of CDK2. Figure 3 shows the cumulative percentages
of positional displacements of ligand molecules relative to each
protein between the docking and final MD structures. From this
figure, it is clear that the docked ligands for CDK2 did not move
very much in the MD simulations, as compared to the other target
proteins, which implies that the protein-ligand interactions were
not fully relaxed. Such insufficiency in conformational relaxation/
refinement directly influences protein-ligand interactions. Partic-
Table 4. Enrichment factors for top 1,000 compounds.
Trypsin HIV PR AChE CDK2
EF (10%) 5.00 (G01) 3.33 (G01) 4.29 (G03) 1.76 (G01)
4.00 (G06) 10.0 (G06) 7.14 (G06) 1.76 (G04)
3.00 (G09) 3.33 (G09) 7.14 (G09) 1.43 (G07)
0.00 (G12) 0.00 (G12) 4.29 (G12) 2.14 (G10)
1.00 (Docking) 5.00 (Docking) 4.29 (Docking) 2.35 (Docking)
0.00 (Rescoring) 1.67(Rescoring) 0.00 (Rescoring) 0.00 (Rescoring)
EF (30%) 2.33 (G01) 2.22 (G01) 1.90 (G03) 1.96 (G01)
3.00 (G06) 3.33 (G06) 2.85 (G06) 1.17 (G04)
2.00 (G09) 2.78 (G09) 2.85 (G09) 1.67 (G07)
0.66 (G12) 0.55 (G12) 2.38 (G12) 1.90 (G10)
1.00 (Docking) 2.78 (Docking) 1.43 (Docking) 1.76 (Docking)
0.33 (Rescoring) 1.67 (Rescoring) 0.48 (Rescoring) 0.19 (Rescoring)
The enrichment factor (EF) can be defined as:
EF~(a=n)=(A=N)
where a is the number of active compounds in the n top-ranked compounds and A is the number of total N compounds. In this table, the n for EF (10%), n for EF (30%),
and N were 100, 300, and 1,000, respectively. For the respective proteins, A, n for EF (10%), and n for EF (30%) indicate the numbers of active compounds in the top
1,000, top 100, and top 300, respectively. All of the EF values calculated from the result of screening using multiple poses. ‘‘Rescoring’’ indicate the result of rescoring
approach (docking) (see Materials and Methods).
doi:10.1371/journal.pcbi.1000528.t004
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simulations were some different from those of experimental
structures (refer to Figures S5 and S6). These data suggested that
the use of MD simulations for CDK2 led to structural
uncertainties for active compounds. In addition, the interactions
of the inactive (decoy) compounds would not be refined fully in
MD simulations. We think that such low mobility for ligand
molecules and the improper conformational dynamics are due to
an improper MD setup. This would be the reason why the
enrichments of the MD simulations using multiple poses were
worse than those of the MM calculations for CDK2.
Discussion
We evaluated the ability to enrich active compounds for four
target proteins: trypsin, HIV PR, AChE, and CDK2. Our
screening approach could improve the molecular docking results
for all of the proteins except CDK2. For trypsin, HIV PR, and
AChE, our results indicated that the use of multiple poses
improved the enrichments of all the MM calculations and MD
simulations. In addition, the binding free energies calculated from
the MD simulations showed higher and more stable enrichments
than those of the docking and MM calculations. In particular, the
G06 using multiple poses was considered to be effective. This
energy contained no entropy components. Further, the enthalpy
components were calculated using the coordinate sets extracted
from the MD simulation of a complex.
Kuhn and coworkers [25] reported that for the MM/PB-SA
values of MM calculations, the strategy of using multiple poses
could only show a high enrichment when the correct binding
mode was contained within the higher-scored docking conforma-
tions, but was not captured with a single pose. In our study, we
carefully selected multiple docking poses by the post-processing of
docking results and used an average of five to six docking poses for
each compound. As a result, the correct binding modes or
potentially correct modes that could be refined by the MD
simulations were sampled within the selected multiple docking
poses, which did not often correspond to the top-scored pose.
Therefore, the results using multiple poses showed a higher
enrichment than those obtained using a single pose.
In addition, Kuhn et al. [25] showed that the use of MD
simulations often leads to structural uncertainties and an
inaccurate estimation of the binding free energy. The MM/PB-
SA energies of the MM calculations and MD simulations in their
study corresponded to G01 and G04 in our study. A comparison
between G01 and G04 indicated that the enrichment of G04 was
lower than that of G01, which is consistent with the results of
Kuhn and coworkers [25], although there were large differences in
the MD setup, MM/PB-SA setup, and target proteins. G01
contained only the enthalpy components that were calculated
using the coordinate sets derived from the MM calculation of a
complex. G04 contained the binding entropy effect of the ligand.
Further, the enthalpy components were calculated using the
coordinate sets from the MD calculation of a complex. The
difference between G04 and G06 was the presence of the entropy
effect. Therefore, we consider that for trypsin, HIV PR, and
AChE, the structural refinement/relaxation by longer and higher
time resolution MD simulations and the relatively accurate
estimation of binding free energy (enthalpy) by the MM/PB-SA
method led to increased enrichment, but the introduction of the
entropy values induced an uncertainty in the binding free energies.
On the other hand, we think that the use of MD simulations for
CDK2 led to structural uncertainties and then an inaccurate
estimation of the binding free energy (Figures S5 and S6). This
would be due to an improper MD setup, as Kuhn and co-workers
suggested in their paper [25].
Basically, it is well-known that it is difficult to calculate entropy
values properly. In our work, the entropy values were calculated
by principal component analysis (PCA). These values are sensitive
to the data sampling frequency [42,43] and are likely to be
overestimated [44]. Therefore, we believe that the entropy values
were slightly unstable and not completely reliable. An alternative
computational method is normal mode analysis. This may be
stable to some extent, but it is known that conformations at
different local energy minima provide rather similar entropy
values even though there are differences in the finite temperature
[42]. Moreover, the computational cost is significantly high to use
for the calculation of many structures. Thus, even if we were to use
normal mode analysis, the entropy values would induce an
uncertainty in the binding free energies. Therefore, in order to
achieve further improved enrichment, it is necessary to improve
the calculations for the entropy terms.
Our strategy could not significantly improve the molecular
docking results for CDK2. It is well known that, as compared to
the binding pockets of the other three proteins, the binding pocket
of CDK2 is more flexible and hydrophobic. We compared the
binding pockets in two different X-ray crystal structures of CDK2
[45,46] (Figure 4). This figure indicates that the shape of the
binding pocket is very flexible and that the hydrophobic region
covers the surface of the binding pocket. In addition, a study on
molecular docking using different CDK2 crystal structures
reported that the volume (flexibility) of the binding site is a key
factor for predicting docking poses [29]. Although only one CDK2
structure was used in this study, we applied MD simulations to
protein-ligand structures obtained from molecular docking to
facilitate the relaxation of protein-ligand interactions. Unfortu-
nately, our MD simulations were insufficient to relax the protein-
ligand conformations in the binding pockets (see Figure 3). Such
insufficiency is believed to be due to the MD setup. To improve
Figure 3. Mobility of ligand molecules in MD simulations. This
graph indicates cumulative percentage graph of positional displace-
ments of ligand molecules relative to the respective proteins between
docking structures and final MD structures. The blue, green, orange,
and red solid lines indicate cumulative curves for trypsin, HIV PR, AChE,
and CDK2, respectively. The broken line indicates a curve for longer MD
simulations (1.4 ns) of CDK2. From the red solid line, it is clear that the
docked ligands for CDK2 did not move in the MD simulations since the
positional displacements of approximately 50% of the ligand confor-
mations were less than 2.0 A ˚.
doi:10.1371/journal.pcbi.1000528.g003
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1.4 ns to each configuration; this simulation time was twice that of
the initial MD simulation time. These MD simulations effected
some relaxation/refinement of the ligand conformations (Figure 3);
the enrichments of the multiple poses were found to be higher than
those of the single pose (Table 2). Despite this, G04–G09 showed
only small improvements in the enrichment performance. These
results suggest that further improvement of the MD setup was
necessary. To obtain information about how to improve the MD
setup, we attempted to maximize the ROC values by using an
approach based on the linear response (LR) [47] and MM/PB-SA
methods (LR-MM/PB-SA approach [48]) The LR-MM/PB-SA
equation was derived from equations 2–4 (see Materials and
Methods):
DGbind~aDEintzbDEelezcDEvdWzdDGPBzeDGSA{fTDSð1Þ
where a, b, c, d, e, and f are weighting factors ranging from 0.5 to
1.5. The terms on the right side of equation 1 represent the energy
difference between the complex and protein plus ligand. This
approach is usually used for estimating the binding affinity by
combining an empirical MM/PB-SA energy calculation with an
LR optimization of coefficients against the experimental binding
affinities of several compounds. The optimized free energy model
is used for interpreting the binding model and predicting the
binding affinity of unknown molecules. In our study, we optimized
the weighting factors to maximize the ROC value, that is, the
enrichment performance, using a genetic algorithm (GA). We
applied the LR-MM/PB-SA approach to the G10 of multiple
poses obtained from the initial MD simulations, because G10
showed the highest ROC value among those of the binding free
energies calculated from the MD simulations (Table 2). As a result,
when the weighting factors of a–f were 1.12, 0.91, 1.47, 1.01, 0.87,
and 1.49, respectively, a maximum ROC value of 0.812 was
obtained (Figure 5). This result suggested that the LR-MM/PB-SA
approach was effective at improving the enrichment performance,
and these weighting factors indicated an improvement plan for the
MD setup. The weighting factor of the entropy term, 1.49, would
contribute to dilute the percentage of inactive (decoy) compounds.
This would be related to the fact that the ligands in the binding
pocket of CDK2 could not move largely (Figure 3). In addition, it
is conceivable that the weighting factor of DEvdW, i.e., 1.47,
enriched the active compounds because they include a hydropho-
bic region and formed comparatively strong hydrophobic
interactions with the binding pocket (See Figure S4). As the
binding modes obtained through MD simulations were some
different from the experimentally observed binding modes, the
conformational refinement was considered insufficient or improp-
er to accurately predict the binding free energy. This information
also suggests that fully conformational relaxation/refinement is
required to improve the enrichment performance. In this study,
the ligand, water molecules, and protein residues around the
binding pocket were allowed to move, but other protein residues
were restrained to the X-ray structure in all of the MM
calculations and MD simulations (a detailed explanation is given
in the Materials and Methods section). Hence, to achieve the
Figure 4. Binding pockets in two different X-ray crystal structures for CDK2. The left figure indicates the binding pocket in the CDK2-
Oxindole inhibitor complex (PDB Id: 1FVV). This structure was used in our study. The right figure indicates the binding pocket in the CDK2-NU2058
inhibitor complex (PDB Id: 1H1P). The hydrophobic regions in the binding pocket are drawn in blue, and the hydrophilic regions are drawn in red.
From this figure, it is clear that large hydrophobic regions were located in both binding pockets. In contrast, the shapes of the two binding pockets
were considerably different, which means that the binding pocket of CDK2 was flexible.
doi:10.1371/journal.pcbi.1000528.g004
Figure 5. ROC curves of the LR-MM/PB-SA approach for CDK2.
This graph shows the sensitivity versus 1-specificity. This indicates the
ROC curves obtained when the active compounds in the top 1,000
compounds are all considered to be as true positive. The black dashed,
sky blue solid, and sky blue dashed lines indicate random screening,
molecular docking and rescoring (docking), respectively. The G01(m),
G01(s), molecular docking and rescoring(docking) are the same as in
Figure 2. G10 (opt) is the ROC curve of G10 (multiple poses) obtained by
the LR-MM/PB-SA approach. The ROC value is 0.812.
doi:10.1371/journal.pcbi.1000528.g005
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allowing wider protein residues to move in MD simulations and
longer MD simulations are required. The former is an especially
important parameter for improving the enrichment performance,
although it would increase the computational cost. In our next
study, which will focus on the extent of the mobility of protein
residues, along with simulation time and force-field parameters for
organic small molecules, we will attempt to optimize the MD setup
using a recent widely used dataset of decoy compounds [49].
The computational screening of large compound libraries
involves the use of hierarchical multiple filters, such as ligand-
and structure-based approaches. Molecular docking plays the
primary role in these filters. With advancements in computer
performance and computational chemistry, docking programs
have become more accurate, but their ability to enrich hit
compounds remains unsatisfactory. In order to improve the
enrichment performance of molecular docking, we attempted to
use the MM/PB-SA method [50] as a post-molecular docking
filter. The basis of our approach was to perform massive MD
simulations of protein-ligand conformations obtained from
molecular docking, aim at the refinement/relaxation of protein-
ligand conformations after docking, and predict more accurate
binding free energies using the MM/PB-SA method in a practical
time for lead discovery. Combining molecular docking and MD
simulations basically allows each of them to neutralize the other’s
defects, but certain problems remain even with MD simulations,
particularly with regard to compound screening applications. The
major drawback of MD simulations is insufficient sampling due to
the significant computational cost involved. To solve this problem,
we performed MD simulations using various docking conforma-
tions obtained by molecular docking. However, the computational
cost of this technique was approximately five to six times that of
MD simulations using single docking conformations, such as the
top-scored docking conformation. The enormous computational
time needed for MD simulations is a serious problem. Here, we
solved this problem by accelerating most of the time-consuming
operations of the MD simulation using a high-performance
special-purpose computer for MD simulations, ‘‘MDGRAPE-3’’
[27,28]. Accordingly, our approach could be performed in a
practical time (about a week) for lead discovery. The evaluation in
this study provides valuable information on in-silico drug design.
Further, a more rigorous MD-based filter is under consideration
for further improving the enrichment performance. This tech-
nique will also be applied to the lead optimization stage of drug
development research.
In conclusion, our approach could improve the enrichment of
virtual screening by molecular docking. Among the 12 types of
binding free energies, G06, which was obtained from the MD
simulations using multiple poses, showed the highest and most
stable ability to enrich the active compounds. The strategy of
multiple poses can be used to sample the potentially correct poses
of active compounds; thus, it increases the enrichment perfor-
mance. Since the G06 enrichment factors for the top 100
compounds ranged from 4 to 10 (see Table 4), which indicates
approximately 1.6–4.0 times higher values than the enrichment
performance of molecular docking, with the exception of CDK2, it
is obvious that a stable and high enrichment can be achieved after
molecular docking. In addition, G06 is suitable for compound
screening because its computational cost is the least among those
of the other MM/PB-SA energies obtained from the MD
simulations. We also confirmed that G01, which was obtained
from the MM calculations, showed good enrichment ability
despite its low computational cost. This result agreed with that of
the previous study [25]. The ability of G01 to enrich active
compounds was lower and less stable than that of G06, but we
believe that G01 acted as an effective filter between molecular
docking and the MD-based MM/PB-SA method. From this study,
we conclude that the application of MD simulations to virtual
screening for lead discovery is effective and practical, but that
further optimization of the MD simulation protocols is required
for the screening of various target proteins, including kinases.
Materials and Methods
Preparation of the Target Protein
We applied our approach to four target proteins: trypsin, HIV
PR, AChE, and CDK2. These structures with crystallographic
resolutions of less than 3.0 A ˚, were retrieved from the Protein
Data Bank (PDB) because the conformations of residues in the
binding pocket affect the molecular docking results (PDB Id: 1C5S
(trypsin) [51], 1HWR (HIV PR) [52], 1E66 (AChE) [53], and
1FVV (CDK2) [46]). All of the bound crystal water molecules,
ligands, and other organic compounds were removed from each
protein. Hydrogen atoms were added, and energy minimizations
on the hydrogen atoms were performed using the Molecular
Operating Environment (MOE) program (Chemical Computing
Group Inc. [54]).
Seeded Compound Library for Docking
For each target protein, we prepared a test set of compounds
that included 10,000 randomly selected compounds, or decoys,
from the Maybridge library of compounds and experimentally
known active compounds. It was confirmed that 95.5% of the
selected decoy compounds obeyed the Lipinski rule of 5 [55]. The
active compounds, which had binding affinities (Ki, Kd,o rI C 50)
below 30 mm, were selected from the PDBbind database [56,57]
and by referring to the literatures [26,58]. Most of the active
compounds also obeyed the Lipinski rule of 5. The numbers of
active compounds selected for each of the respective target
proteins was as follows: 21 (trypsin), 8 (HIV PR), 14 (AChE), and
26 (CDK2) (see Figure S1, S2, S3, S4). For each compound of the
test set, a 3D conformation was generated, ionized, and energy
minimized using LigPrep (Schro ¨dinger Inc. [59]), assuming a pH
of 7.0.
Docking
Molecular dockings were performed using the Genetic Optimi-
sation of Ligand Docking (GOLD) version 3.1 [9,10]. This
program employs a GA to explore the possible binding modes.
The standard default settings for the GA parameters were used.
The binding site radius was 12 A ˚. We performed the docking run
three or four times using the GoldScore or ChemScore function
for each target protein and selected the result that showed the best
enrichment. GoldScore (default settings) was used as the scoring
function for trypsin and HIV PR. In contrast, ChemScore (default
settings) was used for AChE and CDK2 because docking runs
using GoldScore can detect few of the successfully docked active
compounds for AChE and CDK2. For AChE alone, the torsional
rotations of Phe-330 (chi1 and chi2) were treated as flexible in the
docking process. For each docking run, the 10 highest-scoring
docking poses were saved to obtain a variety of binding modes.
Post-processing of the Docking Results
First, among the 10 highest-scoring docking poses saved for
each compound, those in which the compound did not occupy the
binding pocket or did not interact with the important residues
were removed. The latter was used only for trypsin and HIV PR.
The important residues were Asp180 for trypsin and Asp24 in
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reducing the false positives for molecular docking. The docked
compounds were then arranged in descending order from the
highest score with respect to the multiple docking poses, and the
top 1,000 compounds were selected from the test set. Finally, for
the top 1,000 compounds, the docking poses of each compound
were clustered using the root mean square deviation of 0.9 A ˚
(complete link method [60]). After post-processing, approximately
6,000 docking poses were selected for the 1,000 compounds, which
were then used as the initial conformations for MD simulations.
Some active compounds were not ranked in the top 1,000. The
numbers of active compounds in the top-scoring 1,000 were 10, 6,
7, and 17 for trypsin, HIV PR, AChE, and CDK2, respectively. In
addition, the compounds in the top-scoring 1,000 were rescored
with ChemScore (trypsin and HIV PR) or GoldScore (AChE and
CDK2) because it is known that the rescoring approach increases
the enrichment performance [61]. Furthermore, we analyzed
ROC curves using molecular weight as classifier (Figure S7). From
statistical analysis, it is obvious that the differences in the ROC
values between G06 and molecular weight were statistically
significant for trypsin, HIV PR, AChE.
MD Simulation Protocols
We performed MD simulations of each complex (ligand-bound
protein), protein, and ligand to obtain various types of binding free
energies (see the following subsection). The active sites of the
protein-ligand complexes were immersed in an approximately 28–
30 A ˚ sphere of transferable intermolecular potential 3 point
(TIP3P) water [62] molecules. The radius of the water droplet was
selected such that the distance of the atoms of all the docked
compounds from the water wall was greater than 15 A ˚ (see
Figure 6). The total number of atoms in the respective systems was
approximately 8,000–12,000. On the solvent boundary, a half-
harmonic potential (1.5 kcal/mol-A ˚ 2) was applied to prevent the
evaporation of the water molecules. The ligand, water molecules,
and protein residues that were approximately 12 A ˚ of the active
center were allowed to move, but other protein residues were
restrained to the X-ray structure by the harmonic energy term
(1.5 kcal/mol-A ˚ 2) in all of the MM calculations, namely the MM
energy-minimization, and MD simulations. For the simulations of
the ligands, each ligand was immersed in a water droplet, and this
structure was used as the initial structure for the MD simulation of
the ligand. In addition, the simulation of each protein (trypsin,
HIV PR, AChE, and CDK2) was performed in the same manner
as that of the complex.
All of the simulations were performed using AMBER 8.0 [63]
modified for MDGRAPE-3 [27,28]. The ff03 force field [64] was
adopted, and the time step was set at 0.5 fs. To carefully consider
the motion of hydrogen atoms in the interactions between the
ligands and protein residues, no bond length constraint was applied
to solute atoms. The temperature of each system was gradually
increased to 300 K during the first 25 ps, and additional MD
simulations were performed for 700 ps for equilibration. The
temperature was maintained at 300 K by using the method
described by Berendsen et al. [65], and the system was coupled to
a temperature bath with coupling constants of 0.2 ps. The
parameters and charges for the ligands were determined using the
antechamber module version 1.27 of AMBER 8.0 [63] by utilizing the
general atom force field (GAFF) [66] and the AM1-BCC charge
method [67,68]. Although the computational cost of the AM1-BCC
charge method is low, a some difference between the charge and
that of ff03 was noticeable. Since the original GAFF parameters
were insufficient to cope with the parameters of all the ligands, we
filled the missing parameters on the basis of the information on
regarding atom types, bonds, valences, angles, and dihedrals by
using an in-house program (see Text S1). (Note: these parameters
for proteins and small organic molecules are very important to
calculate the binding free energies between proteins and ligands)
Our MDGRAPE-3 system is a cluster of personal computers,
each equipped with two MDGRAPE-3 boards. Each board
contains 12 MDGRAPE-3 chips and has a peak speed of
approximately 2 Tflops. The computations of non-bonded forces
and energies for MD simulations were accelerated by
MDGRAPE-3, and the other calculations were performed by
the host central processing unit (CPU). In this study, we used 50
host computers equipped with 100 MDGRAPE-3 boards. The
calculations for an MD simulation and the estimation of the
binding free energies by the MM/PB-SA method were performed
simultaneously. The average computational time for a single
protein-ligand complex was 2.5 h, and the computations for
approximately 6,000 protein-ligand conformations obtained by
docking for each protein were completed in a week. The total
simulation time for each protein was 4 ms, which corresponded to
an 8-ms MD simulation with a standard time step of 1 fs. A single
MD simulation for the system (Figure 6), without using
MDGRAPE-3, requires more than 10 times the abovementioned
computational time. Thus, in the current state, it would be quite
difficult to use our screening approach without the MDGRAPE-3
system in a practically appropriate time for lead discovery.
Therefore, our study can provide important information for MD-
based screening.
Calculation of Binding Free Energy by the MM/PB-SA
Method
The production MD trajectory was collected for the last period
of 210 ps. In the calculation of the binding free energies by the
Figure 6. System for MD simulation of trypsin. The protein is
shown by the space-filled model, and the ligand is colored blue. The
peripheral residues around the active center (red region), a ligand, and
water molecules were allowed to move in the MD simulation. The
protein residues (grey) were restrained to the X-ray structure by a
harmonic energy term. Similar systems were used for the other target
proteins.
doi:10.1371/journal.pcbi.1000528.g006
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implicit solvation models. The binding free energy was calculated
by the following equations.
DGbind~Gcomplex{(GproteinzGligand) ð2Þ
G~vEMMwzvGPBwzvGSAw{TS ð3Þ
EMM~EintzEelezEvdW ð4Þ
GSA~cAzb ð5Þ
In the above equations, ,.denotes the average for a set of 30
conformations along an MD trajectory. Eint includes the bond,
angle, and torsional angle energies; Eele and EvdW represent the
intermolecular electrostatic and van der Waals energies, respec-
tively. GPB was calculated by solving the PB equation with the
DelPhi program [69,70], using the PARSE radii [71,72] and
AMBER charges. The grid spacing used was 0.5 A ˚. The dielectric
constants inside and outside the molecule were 1.0 and 80.0,
respectively. In equation 5, which calculates the nonpolar
solvation contribution, A is the solvent-accessible surface area that
was calculated using the Michael Sanner’s Molecular Surface
(MSMS) program [73], and c and b are 0.00542 kcal/mol-A ˚ 2 and
0.92 kcal/mol, respectively. The probe radius was 1.4 A ˚. The
conformational entropy term of the solute, TS, was approximated
by a combination of a classical statistics expression and PCA [74],
using the PTRAJ module of AMBER 8.0 [63]. In the PCA
calculation, the last 210 ps (3,000 conformations) of each
production trajectory were used.
The analysis of the binding free energy involved the calculation
of the energies for conformations obtained from the MM (namely,
energy-minimized) coordinates or MD trajectories. When the MM
calculations or MD simulations of a complex, protein, and ligand
were performed, we could obtain various types of binding free
energies by combining the respective coordinate sets. The
enthalpy contributions of Gprotein and Gligand in equation 2 were
calculated in the following 2 ways: (1) by using the coordinate sets
of a protein (or ligand) obtained from the MD simulations (or MM
calculations) of the protein (or ligand) and (2) by using the
coordinate sets extracted from the MD simulation of a complex.
Similar to the enthalpy contribution, the entropy contribution was
calculated by using the MD trajectories. When the entropy
contributions of Gcomplex, Gprotein, and Gligand were calculated by
using the MD trajectory of only the complex, we considered the
entropy contribution of DGbind to be zero because the energy
components were almost cancelled. In this study, in order to
thoroughly investigate which MM/PB-SA energies were suitable
for compound screening, we adopted 12 binding free energies,
G01–G12, to manage the entropy contributions independently of
the enthalpy contributions (see Table 1). It should be noted that
the coordinate sets for calculating the entropy contributions were
not always consistent with those for calculating enthalpy
contributions. Table 1 shows the enthalpy and entropy terms for
computing of Gcomplex, Gprotein, and Gligand in equation 2. We
classified the 12 binding free energies into four categories.
Category 1 contained the energies obtained by the MM
calculations, and categories 2, 3, and 4 contained those obtained
by MD calculations. These categories were classified according to
the combination of coordinate sets used for enthalpy calculations:
G01–G03, G04–G06, G07–G09, and G10–G12 belonged to
categories 1, 2, 3, and 4, respectively. Each binding free energy of
a ligand adopts the minimum energies from among the energies of
multiple poses. Thus, by gathering and arranging their energies,
we were able to assess the enrichment performance of the
screening approach.
Supporting Information
Figure S1 Active compounds of trypsin. The structural formulae
and PDB ids of active compounds used in the seeded compound
library are shown in the following figures. The asterisks represent
the active compounds in top-scoring 1,000.
Found at: doi:10.1371/journal.pcbi.1000528.s001 (0.08 MB
DOC)
Figure S2 Active compounds of HIV PR. The structural
formulae and PDB ids of active compounds used in the seeded
compound library are shown in the following figures. The asterisks
represent the active compounds in top-scoring 1,000.
Found at: doi:10.1371/journal.pcbi.1000528.s002 (0.53 MB
DOC)
Figure S3 Active compounds of AChE. The structural formulae
and PDB ids of active compounds used in the seeded compound
library are shown in the following figures. The asterisks represent
the active compounds in top-scoring 1,000.
Found at: doi:10.1371/journal.pcbi.1000528.s003 (0.06 MB
DOC)
Figure S4 Active compounds of CDK2. The structural formulae
and PDB ids of active compounds used in the seeded compound
library are shown in the following figures. The asterisks represent
the active compounds in top-scoring 1,000. Compounds 1 and 19
were selected by referencing literatures.
Found at: doi:10.1371/journal.pcbi.1000528.s004 (0.11 MB
DOC)
Figure S5 Number of correctly docked conformations in top-
scored active compounds. These indicate the number of correctly
docked conformations in the top-scoring poses for active
compounds obtained from molecular docking, G01, and G06.
The red and blue bars indicate the number of poses within the
root mean square deviations (RMSDs) of 2.5 and 3.5 A ˚ from those
of the experimental structure, respectively. The active compounds
in the top 1,000 were investigated. In G06, the final MD structure
was used.
Found at: doi:10.1371/journal.pcbi.1000528.s005 (0.10 MB
DOC)
Figure S6 Minimal RMSD values of computed poses from
experimental poses for active compounds. The horizontal axis
indicates the index number of active compounds in the top 1,000
shown in Figures S1, S2, S3, S4 and the vertical axis indicates the
minimal RMSD among all the poses. For each protein, the poses
obtained from molecular docking, G01, and G06 were investigat-
ed. In G06, the final MD structure was used. The red bars indicate
the pose within the top-three scoring. For trypsin, HIV PR, and
AChE, it was found that MD simulations could improve the
binding modes and predict better binding free energies. For
CDK2, however, it is suggested that MD simulations lead to
structural uncertainties and an inaccurate estimation of the
binding free energy.
Found at: doi:10.1371/journal.pcbi.1000528.s006 (0.24 MB
DOC)
Figure S7 ROC curves using molecular weight as classifier. This
graph shows the sensitivity versus 1-specificity. This indicates
MD-Based Screening in Drug Design
PLoS Computational Biology | www.ploscompbiol.org 11 October 2009 | Volume 5 | Issue 10 | e1000528ROC curves when the active compounds in the top 1,000
compounds are considered as total the true positives. ROC curves
for trypsin, HIV PR, AChE, and CDK2 were drawn in blue, red,
yellow, and orange, respectively. These ROC values for trypsin,
HIV PR, AChE, and CDK2 are 0.454, 0.674, 0.462, and 0.430.
From statistical analysis, it is obvious that the differences in the
ROC values between G06 and molecular weight were statistically
significant for trypsin, HIV PR, AChE. The differences in the
ROC values between molecular docking and molecular weight
were not statistically significant for all proteins.
Found at: doi:10.1371/journal.pcbi.1000528.s007 (0.08 MB
DOC)
Text S1 Assignment of missing force field parameters. We filled
in the following missing parameters on the basis of the information
on regarding atom types, bonds, valences, angles, and dihedrals by
using an in-house program.
Found at: doi:10.1371/journal.pcbi.1000528.s008 (0.06 MB
DOC)
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